Amgen has bowed out of a $180 million collaboration with Cambridge, MA-based Bind Therapeutics, ending work on a new therapy for solid tumors by amping up an Amgen drug with the biotech’s nanoengineering technology. News of the research setback–which ends the first big pact inked for the biotech’s delivery tech–took a bite out of Bind’s shares, sending its stock down by more than 10%.

…read more

Source: Bind shares slide after Amgen walks out of $180M collaboration deal


0 No comments